• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nektar Therapeutics (NQ: NKTR )

    1.400 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Nektar Therapeutics

    < Previous 1 2 3 4 5 Next >
    The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Expert Ratings for Nektar Therapeutics
    Within the last quarter, Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings: 
    Via Benzinga
    Nektar Therapeutics's Return On Capital Employed Insights
    According to Benzinga Pro data, during Q1, Nektar Therapeutics (NASDAQ:NKTR) posted sales of $24.82 million. Earnings were up 37.94%, but Nektar Therapeutics still reported an overall loss of $90.39... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Gainers 
    Via Benzinga
    The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
    Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
    Via Benzinga
    After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring
    Via Benzinga
    The Daily Biotech Pulse - Tuesday, April,26
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Talk Markets
    The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide
    U.S. stocks traded higher in volatile session, with the Dow Jones gaining around 60 points toward the end of trading on Monday. 
    Via Benzinga
    Expert Ratings for Nektar Therapeutics
    Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: 
    Via Benzinga
    68 Biggest Movers From Yesterday
    Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Gainers Natus Medical (NASDAQ:NTUS) shares rose 28.8% to $33.55 during Monday's regular session. The current volume of 3.0 million shares is 2073.2% of Natus Medical... 
    Via Benzinga
    Mid-Day Market Update: U.S. Stocks Turn Lower; Bank of America Earnings Top Views
    U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. 
    Via Benzinga
    34 Stocks Moving In Monday's Mid-Day Session
    Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.... 
    Via Benzinga
    Why Nektar Shares Are Down Almost 35%
    Shares of Nektar Therapeutics (NASDAQ: NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in... 
    Via Benzinga
    Mid-Morning Market Update: Markets Open Higher; Dow Gains 100 Points
    U.S. stocks traded higher this morning, with the Dow Jones adding around 100 points on Monday. 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
    Upgrades 
    Via Benzinga
    Benzinga's Daily Brief On Trending Tickers For April 18, 2022: Casa Systems, Twitter, DiDi Global, And More
    Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Gainers Natus Medical (NASDAQ:NTUS) stock rose 28.3% to $33.42 during Monday's pre-market session. The market value of their outstanding shares is at $1.1 billion.... 
    Via Benzinga
    Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Gainers 
    Via Benzinga
    Best Performers Since 3/14 Pivot
    Early last week, the US equity market pivoted, gaining 1%+ for four consecutive days between last Tuesday and last Friday. Sentiment has shifted amongst the investing community for the time being. 
    Via Talk Markets
    The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
    Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
    Via Benzinga
    What 4 Analyst Ratings Have To Say About Nektar Therapeutics
    Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ:NKTR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
    Via Benzinga
    Where Nektar Therapeutics Stands With Analysts
    Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
    Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the... 
    Via Benzinga
    10 Biggest Price Target Changes For Tuesday
    Wells Fargo cut the price target on Coupa Software Incorporated (NYSE: LPI) from $190 to $80. Laredo Petroleum shares fell 29.8% to $63.10 in pre-market trading. 
    Via Benzinga
    96 Biggest Movers From Yesterday
    Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share. Incannex... 
    Via Benzinga
    Mid-Afternoon Market Update: Dow Turns Negative; Turquoise Hill Resources Shares Spike Higher
    U.S. stocks turned lower toward the end of trading on Monday as the Dow Jones dropped 100 points, after surging more than 400 points earlier during the session. The Dow... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 48.0% to $20.95 during Monday's regular session. The company's market cap stands at $1.0 billion.... 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.